Valeant Pharmaceuticals reported that its lenders have agreed to an amendment to the company’s covenants on its $31 billion of debt.

Investors in Valeant’s loans agreed to the changes in exchange for a higher interest rate and a fee. The company noted it obtained another amendment earlier this year to help stave off default.

Barclays Bank was reported to have arranged the amendment. Valeant will increase the interest rate it pays lenders by 50 basis points and it will also pay a 25 basis point amendment fee.